• 16 June 2020
    Sequana Medical announces that the results of the alfapump® MOSAIC study have been published in Liver Transplantation

    Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces that the results of MOSAIC, the North American feasibility study of the alfapump in recurrent and refractory liver ascites, have been published in Liver Transplantation, the peer-reviewed publication of the American Association for the Study of Liver Diseases.

    The publication entitled “Improvement in Quality of Life and Decrease in Large-Volume Paracentesis Requirements with the Automated Low-Flow Ascites Pump” concluded that the alfapump appears to be a promising treatment for refractory ascites in cirrhosis, especially in patients who are not TIPS candidates.

    Prof. Florence Wong, investigator of the MOSAIC study and lead author of the Liver Transplantation article, said: “We are glad to have the opportunity to present the results of MOSAIC in this respected peer-reviewed journal. We found that the alfapump system is a feasible treatment for recurrent ascites in patients with cirrhosis who are not suitable for TIPS insertion, especially in those with relatively preserved liver function, and has the potential to improve their day-to-day lives.”

    Ian Crosbie, CEO of Sequana Medical, added: “The publication of the MOSAIC data in this peer-reviewed journal further supports use of our alfapump and its potential to address major and urgent unmet medical needs in liver cirrhosis. The designation of Breakthrough Device status by the FDA and the forecast growth in liver cirrhosis due to NASH makes the need for improved treatment options all the more important. The pivotal North American POSEIDON study, intended to support a commercial marketing application of the alfapump in the U.S. and Canada, is underway and we look forward to making our innovative alfapump available for patients suffering from this severe and underserved medical condition.”